Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-7 of 7 for

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. Phase 2 Study To Evaluate Safety And Efficacy Of Cretostimogene Grenadenorepvec In NMIBC

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. Safety And Efficacy Study Of Intravesical Instillation Of TARA-002 In Adults With High-grade Non-muscle Invasive Bladder Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. Testing The Addition Of An Anti-Cancer Drug, Gemcitabine, To Usual Treatment (BCG Alone) In People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. LEGEND Study: EG-70 In NMIBC Patients BCG-Unresponsive And High-Risk NMIBC Incompletely Treated With BCG Or BCG-Naïve

    Scottsdale/Phoenix, AZ, Rochester, MN

  5. Trial Of Nadofaragene Firadenovec Vs. Observation In Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. ResQ132EX-NMIBC: Expanded Access Use Of Recombinant Bacillus Calmette-Guerin In Nonmuscle Invasive Bladder Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  7. An Expanded Access Program Of Cretostimogene Grenadenorepvec For Treatment Of NMIBC For Patients Unresponsive To BCG

    Rochester, MN

.

Mayo Clinic Footer